Cunningham R F, Perel J M, Israili Z H, Dayton P G
Drug Metab Dispos. 1977 Mar-Apr;5(2):205-10.
The metabolism of probenecid in vitro was investigated with rat, mouse, and human liver preparations. As in previous in vivo studies, metabolism in vitro was found to be limited to the side chain. This metabolism involved mono-N-depropylation and hydroxylation in the 2- and 3-positions (3-hydroxy probenecid was in part converted to the carboxy metabolite). Acyl glucuronide conjugation was minimal. The presence of multiple forms of microsomal oxidative enzymes was suggested by the effects of: a) phenobarbital pretreatment, b) drug-metabolizing enzyme inhibitors, and c) variations in ionic strength and buffer composition on the metabolism of probenecid.
采用大鼠、小鼠和人肝脏制剂对丙磺舒的体外代谢进行了研究。与之前的体内研究一样,发现体外代谢仅限于侧链。这种代谢涉及单-N-去丙基化以及2位和3位的羟基化(3-羟基丙磺舒部分转化为羧基代谢物)。酰基葡萄糖醛酸结合作用极小。丙磺舒代谢受以下因素影响,提示存在多种形式的微粒体氧化酶:a)苯巴比妥预处理;b)药物代谢酶抑制剂;c)离子强度和缓冲液组成的变化。